HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

orlistat (Xenical)

isolated from Streptomyces toxytricini; inhibits 3C protease, viral

Also Known As:

Xenical; tetrahydrolipstatin; 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate; Alli; GlaxoSmithKline brand of orlistat; Hoffmann-La Roche brand of orlistat; Roche brand of orlistat; THLP; L-Leucine, N-formyl-, 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester, (2S-(2alpha(R*),3beta))-

Networked: 773 relevant articles (140 outcomes, 216 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Lactones: 258
  - orlistat: 773

Experts

1.	Tziomalos, Konstantinos: 9 articles (03/2014 - 05/2006)
2.	Filippatos, T D: 9 articles (10/2010 - 02/2005)
3.	Katsikis, Ilias: 8 articles (03/2014 - 01/2007)
4.	Panidis, Dimitrios: 8 articles (03/2014 - 01/2007)
5.	Elisaf, M S: 8 articles (10/2010 - 02/2005)
6.	Bray, George A: 7 articles (08/2014 - 06/2002)
7.	Rössner, S: 7 articles (05/2014 - 01/2000)
8.	Elisaf, Moses S: 7 articles (11/2011 - 05/2006)
9.	Rissanen, Aila: 7 articles (01/2010 - 06/2003)
10.	Kiortsis, D N: 7 articles (12/2008 - 02/2005)

Related Diseases

1.	Weight Loss (Weight Reduction) 01/01/1998 - "Orlistat, an inhibitor of pancreatic lipases, has proven effective for weight reduction in obese patients. " 01/01/2006 - "The weight loss was significantly greater in the orlistat group than in the placebo group for the entire study period (P < 0.001). " 12/01/2005 - "Orlistat-treated patients achieved significantly greater weight loss at the study end than placebo-treated patients (-5.4 vs. -2.4 kg; P<0.0001). " 01/01/2003 - "In randomized, controlled trials of up to 2 years' duration, orlistat plus a hypocaloric diet produced significantly greater weight loss than placebo (P < 0.001). " 10/01/2000 - "In a series of 1- and 2-yr randomized, placebo-controlled trials of obese subjects, treatment with orlistat in combination with a mildly calorie-restricted diet consistently produced significantly greater mean weight loss than diet alone. "
2.	Obesity 01/01/2006 - "Xenical is beneficial for patients with DM-2 and obesity because it improves metabolic processes." 01/01/2002 - "[Efficacy of orlistat in the treatment of constitutional-alimentary obesity in patients with high risk of cardiovascular complications]." 01/01/2000 - "Several obesity-related risk factors improved significantly more with orlistat treatment than with placebo. " 10/01/1999 - "In a study of patients with obesity associated with type 2 diabetes, patients treated with orlistat lost more weight and had improved serum lipid profiles compared with placebo recipients. " 03/01/2009 - "Orlistat, an inhibitor of digestive lipases, is widely used for the treatment of obesity. "
3.	Body Weight (Weight, Body) 08/01/2010 - "We also recorded a significant reduction of body weight and BMI with orlistat, but not with placebo. " 04/01/1998 - "Orlistat resulted in a significantly greater mean loss of body weight than observed in the placebo group. " 04/01/2005 - "The aim of this study was to assess safety, tolerability and efficacy of orlistat treatment in comparison with placebo in the reduction of body weight in obese subjects and the related cardiovascular risk factors. " 01/01/2003 - "The results of this study demonstrate that orlistat improved endothelial function, weight, body mass index and systolic and diastolic blood pressure in young women." 07/01/2012 - "Result showed respective decrease of 12.78% and 38.51% in body weight gain, of VA fed rats against 17.45% of orlistat at end of study (P < 0.05); but with no effect on food intake. "
4.	Overweight 01/01/2003 - "Adding orlistat as a pharmacological treatment to conventional diabetes and weight management approaches seems to be a cost-effective treatment option for overweight and obese patients with type 2 diabetes." 12/01/2015 - "The aim of this study was to review the evidence of the effects of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes. " 04/01/2014 - "The primary objective of this study was to evaluate the effect of orlistat on the weight and body mass index of obese and overweight Korean patients. " 04/01/2012 - "This study's objective was to examine the effect of a 6-month, standard education-based weight-management program with and without orlistat 60 mg on changes in weight and body fat in overweight soldiers. " 08/01/2006 - "Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study."
5.	Insulin Resistance 10/01/2007 - "Insulin resistance index and malonyl dialdehyde levels improved significantly after orlistat therapy, whereas HbAic remained unchanged. " 04/01/2012 - "Orlistat improved lipid profile and led to faster glycaemic control and insulin resistance parameters than the control, without any serious adverse event. " 04/01/2012 - "Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes." 05/01/2006 - "Treatment with orlistat + diet was associated with significant effects on WC, TG, and level of insulin resistance, but not BAR." 10/01/2005 - "Noninvasive hemodynamic parameters including arterial compliance were measured using radial artery pulse wave analysis, at the beginning and 1 month after taking the last dose of Orlistat, and insulin resistance was calculated using HOMA score. "

Related Drugs and Biologics

1.	sibutramine (Meridia)
2.	Glucose (Dextrose)
3.	Insulin (Novolin)
4.	Metformin (Glucophage)
5.	Cholesterol
6.	Lipase (Acid Lipase)
7.	orlistat (Xenical)
8.	Anti-Obesity Agents (Antiobesity Drugs)
9.	Lipoproteins (Lipoprotein)
10.	Acarbose

Related Therapies and Procedures

1.	Fat-Restricted Diet (Diet, Fat Restricted)
2.	Drug Therapy (Chemotherapy)
3.	Caloric Restriction
4.	Bariatric Surgery
5.	Diet Therapy (Therapy, Diet)